Home / Companies / 4D Molecular Therapeutics, Inc. / 21 May 2024
4D Molecular Therapeutics, Inc.: meeting of 21 May 2024
Votes reported on Form N-PX, item by item
90 Form N-PX filers reported votes at the 4D Molecular Therapeutics, Inc. meeting of 21 May 2024. Their records fall into 2 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
1 nominee; 60.4% of reported votes for; 38 filers withheld from or voted against at least one nominee.
168 vote records from 90 filers. 34 of the 89 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
168 vote records from 90 filers. 0 of the 89 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
How the largest families voted
| Family | 1. Directors | 2. Auditor |
|---|---|---|
| Vanguard | For | For |
| BlackRock and iShares | For | For |
| Fidelity | For | For |
| Dimensional | Abstain or withhold * | For |
| State Street and SPDR | For | For |
| Franklin Templeton | For | For |
| Invesco | For | For |
| Equitable | For | For |
| Charles Schwab | For | For |
| Nuveen and TIAA | For | For |
| ProShares and ProFunds | Abstain or withhold * | For |
| John Hancock and Manulife | Abstain or withhold * | For |
| Morgan Stanley, Eaton Vance and Calvert | Abstain or withhold * | For |
| Goldman Sachs | Abstain or withhold * | For |
| Jackson National funds | Abstain or withhold * | For |
| Northern Trust and FlexShares | For | For |
| SEI | For | For |
| T. Rowe Price | For | For |
| Lincoln Financial | For | For |
| Voya | Abstain or withhold * | For |
| First Trust | Abstain or withhold * | For |
| Nationwide | Abstain or withhold * | For |
| Victory Capital | Abstain or withhold * | For |
| Brighthouse Funds | Abstain or withhold * | For |
| Guggenheim and Rydex | Abstain or withhold * | For |
| BNY Mellon | Abstain or withhold * | For |
| Principal | Abstain or withhold * | For |
| Pacific Life funds | For | For |
| Global X | For | For |
| DWS | Abstain or withhold * | For |
| Allspring | Abstain or withhold * | For |
| Janus Henderson | Abstain or withhold * | For |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the 4D Molecular Therapeutics, Inc. meeting?
90 Form N-PX filers reported votes at the meeting of 21 May 2024. The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by 4D Molecular Therapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for 4D Molecular Therapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing 4D Molecular Therapeutics, Inc. with a meeting date within three days of 21 May 2024. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.